logo
Weight loss drugs may lower risk of dementia, stroke: Study

Weight loss drugs may lower risk of dementia, stroke: Study

The Hill5 days ago
Some popular weight loss drugs may lower the risk of dementia and stroke for patients with Type 2 diabetes and obesity, new research published in JAMA Network suggests.
Patients taking semaglutide or tirzepatide medications — active ingredients in weight loss drugs such as Ozempic, Mounjaro and Wegovy — showed a lower risk of developing certain diseases compared to those taking other, similar medications.
Those include neurodegenerative diseases, such as dementia and Alzheimer's, and cerebrovascular disease, which manifests in strokes, brain aneurysms and more.
Researchers analyzed the health developments over seven years in 60,000 adults aged 40 or older diagnosed with both Type 2 diabetes and obesity, as recorded by the TriNetX U.S. network.
The patients were all users of semaglutide, tirzepatide or other GLP-1 anti-diabetes drugs from December 2017 through June 2024.
The effects were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.
Researchers acknowledged more clinical trials are needed to corroborate their initial findings, but they maintained the data 'represents one of the most recent clinical database–driven analyses to investigate the neuroprotective and cerebrovascular associations of newer GLP-1RAs' for some patients.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Alzheimer's risk could rise with specific sleep pattern, experts warn
Alzheimer's risk could rise with specific sleep pattern, experts warn

New York Post

time13 minutes ago

  • New York Post

Alzheimer's risk could rise with specific sleep pattern, experts warn

A new study has found a link between rapid eye movement (REM) sleep and Alzheimer's disease. The research from China, published in the journal Alzheimer's & Dementia by the Alzheimer's Association, analyzed the sleep cycles of 128 adults in varying states of cognition. Advertisement The study found that the highest occurrence of REM latency — which is when it takes longer for someone to reach the first REM period after drifting off to sleep — was associated with the highest risk of Alzheimer's. The researchers concluded that prolonged REM latency may serve as a 'novel marker of risk factor' for Alzheimer's disease and related dementias. Dr. Wendy Troxel, senior behavioral scientist at the RAND Corporation in California, said this study adds to 'growing evidence' that specific sleep features, like prolonged REM sleep, are linked to Alzheimer's biomarkers. 'REM sleep is the stage of sleep when dreams mostly occur, and is critically important for memory consolidation and emotional processing,' Utah-based Troxel, who is also author of 'Sharing the Covers: Every Couple's Guide to Better Sleep,' told Fox News Digital. Advertisement This new research aligns with findings from Troxel's own lab, which have shown that other signs of poor sleep health — like shorter duration and poor quality — are associated with worse cognitive function. 'Sleep disruptions may contribute to the buildup of amyloid and tau proteins, key features of Alzheimer's pathology,' the sleep expert said. 5 A new study has found a link between rapid eye movement (REM) sleep and Alzheimer's disease. amenic181 – 'But it's also important to note that the Alzheimer's disease process itself can disrupt sleep, suggesting a bidirectional association between sleep problems and cognitive decline.' Advertisement Dr. Giulio Taglialatela, vice president and research institute director of the Brain Health Institute at the University of Texas Medical Branch, reacted to these findings in a separate interview with Fox News Digital. Taglialatela said it's been 'long understood' that getting a good night's sleep is associated with a lower risk of developing dementia. 'Our brains use sleep to clear out toxic proteins, like those associated with Alzheimer's, and these results show that the cleaning mechanism is less effective when it takes someone longer to enter the REM cycle,' he noted. 5 The study found that the highest occurrence of REM latency was associated with the highest risk of Alzheimer's. – Advertisement 'Unfortunately, there is nothing an individual can do to control how long it takes to enter REM sleep,' the expert.' However, the expert said, the findings provide a 'promising avenue' for predicting the likelihood of someone eventually developing dementia. 'Early intervention in Alzheimer's is essential for delaying its progression, and measuring REM sleep could be a marker to indicate who may be a candidate for treatment even before they start to show impaired cognitive function,' Taglialatela said. Potential limitations 5 'Our brains use sleep to clear out toxic proteins, like those associated with Alzheimer's, and these results show that the cleaning mechanism is less effective when it takes someone longer to enter the REM cycle,' Dr. Giulio Taglialatela noted. sudok1 – The study did have some limitations, the researchers acknowledged – primarily that it was cross-sectional, 'and thus the direction of the association cannot be determined.' The sample size was also relatively small, and the researchers only focused on one specific type of tau protein. There is also the possibility that monitoring sleep in a clinical setting may introduce 'environmental disturbances,' impacting sleep measurement accuracy, the researchers noted. 'Future studies will benefit from research in real-world home settings,' they wrote. Tips for sleep improvements 5 The study did have some limitations, the researchers acknowledged – primarily that it was cross-sectional, 'and thus the direction of the association cannot be determined.' LIGHTFIELD STUDIOS – Advertisement While these findings are important, Troxel said, she encourages individuals to not allow the information to be 'another source of worry that keeps you awake at night.' 'Avoid the tendency to become overly fixated on metrics like REM sleep percentage or latency from consumer sleep trackers, as they have limited accuracy in determining sleep architecture,' she cautioned. 'Obsessing on such data can increase anxiety, which is a powerful sleep disruptor.' Every morning, the NY POSTcast offers a deep dive into the headlines with the Post's signature mix of politics, business, pop culture, true crime and everything in between. Subscribe here! The best approach is to focus on the foundations of good sleep health, the expert said. Advertisement Adults should strive for seven to nine hours of shuteye and should maintain consistent sleep and wake times, according to Troxel. 5 Adults should strive for seven to nine hours of shuteye and should maintain consistent sleep and wake times, according to experts. Satawat – 'Minimize common disruptors such as excessive caffeine and alcohol, which are known to fragment REM sleep, [as well as] screen use before bedtime,' she added. Advertisement 'Focusing on these core sleep habits is the most effective and evidence-based way to support the brain and overall health.' Taglialatela also encourages individuals to focus on creating an 'ideal sleep environment' while maintaining 'good bedtime habits' to reduce the risk of developing Alzheimer's.

FDA Appoints Biotech Executive as Top Drug Regulator Under RFK Jr.
FDA Appoints Biotech Executive as Top Drug Regulator Under RFK Jr.

Los Angeles Times

time43 minutes ago

  • Los Angeles Times

FDA Appoints Biotech Executive as Top Drug Regulator Under RFK Jr.

Food and Drug Administration commissioner Marty Makary has chosen former biotech executive George Tidmarsh as the agency's top drug regulator, the agency confirmed Monday. Tidmarsh, an adjunct professor of pediatrics and neonatology at Stanford University, will serve as director of the Center for Drug Evaluation and Research, one of the FDA's largest and most important divisions with a staff of about 5,700 that reviews the vast majority of new drug applications. Jacqueline Corrigan-Curay, the acting head of the CDER, recently announced she was leaving the agency. Tidmarsh, 65, was involved in the development of several approved drugs, likely making him a reassuring choice for a pharmaceutical industry that's facing pressure from the Trump administration to lower prices and move manufacturing to the US. Tidmarsh's appointment 'brings in a generally well-respected, credible industry veteran, we believe helping fill a key regulatory void,' Brian Abrahams, an analyst at RBC Capital Markets, said in a note to clients. While recent cuts at the agency have raised concerns about the FDA's drug approval process, 'we would expect Tidmarsh to be a pragmatic officer who will likely build upon current practice to ensure continuity and potentially be an advocate for the industry.' Among the controversies Tidmarsh will contend with is the agency's accelerated approval process. The use of this expedited pathway to get drugs green lit has skyrocketed in recent years and been criticized for sometimes letting unproven treatments linger on the market for too long. Advocates say speeding up the process gets drugs quickly to patients suffering from serious diseases. Tidmarsh is also primed to be a key player in reassessing the agency's approach to regulating prescription drug advertising. Health Secretary Robert F. Kennedy Jr. has long been a critic of direct-to-consumer drug advertising, and Makary has indicated that the agency is reviewing its approach to regulating such ads. During a panel on censorship and scientific speech at Stanford last year, Tidmarsh raised concerns about the FDA's inconsistent regulation of pharmaceutical products. He pointed to the agency's long-standing restrictions on off-label communication by manufacturers and questioned some vaccine makers' ads during the pandemic.'This discrepancy shows that FDA may apply free speech regulation at a whim and inconsistently,' he said. While the FDA's vaccine division has been in the spotlight recently over Covid shots, the drug division has made some of the agency's most controversial decisions. In the '90s, CDER approved language allowing opioid drugs, such as OxyContin, to be widely marketed — despite a lack of substantial evidence supporting their long-term effectiveness. The move helped pave the way for the opioid epidemic. The division also caused a firestorm after approving the Alzheimer's treatment Aduhelm that hadn't clearly been proven to work in research studies. On a recent podcast, Tidmarsh said he met Makary at a conference last fall at Stanford. It featured many people critical of restrictions and mandates during the pandemic, several of whom now have top government health jobs. Tidmarsh appears to share Makary's concerns about a lack of dissenting viewpoints in science. In a podcast about a year ago, he said academics foster a culture that is reluctant to question prevailing views and that grantmaking has become concentrated into a few hands. On LinkedIn last year, Tidmarsh wrote that 'academic science has become riddled with fraud, the time has come to root out the corruption.' He funds the Sleuth in Residence program that supports scientific fraud investigators at the website Retraction Watch, which tracks academic journals. At Stanford, Tidmarsh got both his medical degree and a PhD in cancer biology and then worked in the school's clinical faculty. He also had a series of biotech jobs, including chief executive officer for La Jolla Pharmaceutical Co., which developed a drug to treat sepsis and is now part of Innoviva Inc. Tidmarsh, who was also trained in pediatric oncology, has worked over the years to find solutions to shortages of old lifesaving cancer drugs. In an interview last year with a publication for doctors, he likened the US generic drug market to a 'wild west' where predatory contracting practices can drive out manufacturers. Langreth and Hornblower write for Bloomberg.

FDA taps biotech industry veteran as RFK Jr.'s top drug regulator
FDA taps biotech industry veteran as RFK Jr.'s top drug regulator

CNBC

time2 hours ago

  • CNBC

FDA taps biotech industry veteran as RFK Jr.'s top drug regulator

The Food and Drug Administration said on Monday it has appointed former biotech executive George Tidmarsh as the agency's top drug regulator. Tidmarsh, an adjunct professor of pediatrics and neonatology at Stanford University's School of Medicine, Fpauswill lead one of the biggest and most crucial divisions of the FDA, which reviews the vast majority of new drug applications. The Center for Drug Evaluation and Research, or CDER, regulates over-the-counter and prescription treatments, including biologic therapies and generics. The acting head of CDER, Jacqueline Corrigan-Curay, announced in June she was retiring. Tidmarsh will step in as the FDA and its regulatory process face massive upheaval under Health and Human Services Secretary Robert F. Kennedy Jr. Kennedy has pursued deep staff cuts across HHS and, in some cases, brought in new employees who either lack relevant scientific and medical experience or share his skepticism of vaccines. But Tidmarsh's extensive background in the industry and involvement in the development of seven now-approved drugs is likely a sigh of relief for the pharmaceutical industry. His previous comments signal that he could take a more hardline approach to regulating drugs. In an opinion piece in April, Tidmarsh slammed regulatory decisions made by a key official pushed out of the FDA under Kennedy, Peter Marks. That includes supporting the accelerated approval of Biogen's ill-fated Alzheimer's drug, Aduhelm, and overruling FDA staff to expand approval of Sarepta Therapeutics' Duchenne muscular dystrophy treatment Elevidys. Last week, the FDA asked Sarepta Therapeutics to halt all shipments of Ele­vidys after three patients died from liver failure after taking it or a similar treatment. The company later said it would not stop shipments to treat patients with the condition who can still walk, saying data show "no new or changed safety signals" within that group. Tidmarsh will likely have a say on that controversial accelerated approval process and the FDA's approach to prescription drug advertising. He served as CEO of La Jolla Pharmaceuticals and Horizon Pharma, the latter of which he founded before Amgen bought it for $28 billion. Tidmarsh also founded Threshold Pharmaceutical, and held senior positions at other biotech companies. "Dr. Tidmarsh is an accomplished physician-scientist and leader whose experience spans the full arc of drug development—from bench to bedside," said FDA Commissioner Dr. Marty Makary, in a statement. "His appointment to lead CDER brings exceptional scientific, regulatory, and operational expertise to the agency."

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store